	Fiscal Year Ended
	October 31, 2020			October 31, 2019			October 31, 2018
Domestic	$	(45.6	)	$	(16.5	)	$	5.2
Foreign		(0.5	)		(0.1	)		(3.0	)
(Losses) income before (benefit) provision for income taxes	$	(46.1	)	$	(16.6	)	$	2.2

	Fiscal Year Ended
	October 31, 2020			October 31, 2019			October 31, 2018
Current:
Federal	$	10.4		$	0.4		$	(6.8	)
State		1.8			1.1			0.1
Foreign		—			—			—
Total Current	$	12.2		$	1.5		$	(6.7	)
Deferred:
Federal		(24.0	)		(4.0	)		(6.4	)
State		(3.8	)		(1.0	)		0.9
Foreign		—			—			1.4
Total Deferred		(27.8	)		(5.0	)		(4.1	)
Benefit for income taxes	$	(15.6	)	$	(3.5	)	$	(10.8	)

Income tax (benefit) provision at the federal statutory rate is reconciled to the Company’s benefit for income taxes as follows:

	Fiscal Year Ended
	October 31, 2020			October 31, 2019			October 31, 2018
Income tax (benefit) provision at federal statutory rate	$	(9.7	)	$	(3.5	)	$	0.5
Taxes on foreign income which differ from the U.S. statutory rate		—			—			(0.3	)
State (benefit) expense		(2.3	)		(0.2	)		0.5
CARES Act impact		(3.5	)		—			—
Manufacturing and research incentives		(0.9	)		(0.6	)		(2.7	)
Nondeductible items		0.8			0.2			0.7
Uncertain tax positions		0.4			(0.1	)		(0.4	)
Valuation allowance		0.2			—			2.2
Remeasurement of deferred taxes - U.S. Tax Reform		—			—			(11.3	)
Bargain purchase gain		(2.2	)		—			—
Stock-based compensation		1.4			0.8			—
Other items		0.2			(0.1	)		—
Benefit for income taxes	$	(15.6	)	$	(3.5	)	$	(10.8	)

Tax benefit for fiscal year 2020 was favorably impacted by tax benefits related to loss carryback allowable under the CARES Act and the nontaxable gain on the acquisition of Spartan ER. Tax benefit was also favorably impacted by incentives for U.S. research and unfavorably impacted by share-based compensation tax deductions.

Tax benefit for fiscal year 2019 was favorably impacted by incentives for U.S. research and unfavorably impacted by share-based compensation tax deductions.

Tax benefit for fiscal year 2018 was favorably impacted by the decrease in the U.S. tax rate and revaluation of net deferred tax liabilities, both as a result of tax legislation in the United States. Tax benefit was also favorably impacted by tax incentives for U.S. manufacturing and research, some of which can be attributed to federal provision-to-return adjustment. Tax benefit was unfavorably impacted by the addition of a valuation allowance on the deferred tax assets in Brazil.

No items included in Other items in the income tax reconciliation above are individually, or when appropriately aggregated, significant.

On December 22, 2017, the Tax Reform Act was signed into law by President Trump. The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018, while also repealing the deduction for domestic production activities, limiting interest expense deductions, implementing a territorial tax system, and creating new taxes on certain foreign-sourced earnings. In fiscal year 2018, the Company recorded $11.3 million of cumulative tax benefit related to remeasurement of net deferred tax liabilities

On March 27, 2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). The Cares Act is an emergency stimulus package that includes spending and tax benefits to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, allowing for net operating loss carrybacks for certain past and future losses, increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Reform Act. The Company evaluated the impact of the CARES Act and recorded a cumulative tax benefit of $3.5 million for the carryback of the fiscal year 2018 federal net operating loss. As the Company is carrying the losses back to years beginning before January 1, 2018, the tax benefit of $3.5 million is a result of the rate differential between the previous 35% federal tax rate and current statutory rate of 21%.

Temporary differences and carryforwards that give rise to deferred tax assets and liabilities include the following items:

	Fiscal Year Ended
	October 31, 2020			October 31, 2019
Deferred tax assets:
Product warranty	$	6.4		$	5.8
Inventory		6.5			5.0
Deferred employee benefits		5.0			4.3
Net operating loss and credit carryforwards		4.9			13.3
Other reserves and allowances		5.9			3.2
Gross deferred tax assets		28.7			31.6
Less: valuation allowance		(1.7	)		(2.1	)
Deferred tax assets		27.0			29.5
Deferred tax liabilities:
Intangible assets		(24.5	)		(26.5	)
Property, plant and equipment		(4.6	)		(16.3	)
Other		(0.8	)		(2.0	)
Deferred tax liabilities		(29.9	)		(44.8	)
Net deferred tax liability	$	(2.9	)	$	(15.3	)

The net deferred tax assets/ (liabilities) recorded in the consolidated balance sheet are as follows:

	Fiscal Year Ended
	October 31, 2020			October 31, 2019
Noncurrent deferred tax asset	$	—		$	0.1
Noncurrent deferred tax liability		(2.9	)		(15.4	)
Net deferred tax liability	$	(2.9	)	$	(15.3	)

At October 31, 2020, the Company has net operating loss carryforwards for U.S. federal income tax purposes of $3.2 million, which are subject to annual limitations and begin to expire in 2029. The Company has state net operating loss carryforwards of $21.6 million, which begin to expire in 2027. The Company also has net operating loss carryforwards generated in Canada and Brazil of $0.6 million and $3.7 million, respectively which are offset by a valuation allowance because the losses are projected to expire prior to being utilized. The Company has state tax and other credit carryforwards of $2.3 million, which begin to expire in 2023.

The Company, or one of its subsidiaries, files income tax returns in the U.S, Canada, Brazil, Singapore and various state jurisdictions. With few exceptions, fiscal years 2016, 2017, 2018 and 2019 remain open to tax examination by Brazilian, Canadian and U.S. federal and state tax authorities. The Company regularly assesses the likelihood of an adverse outcome resulting from examinations to determine the adequacy of its tax reserves.

A reconciliation of the beginning and ending amount of unrecognized tax benefits are as follows:

	Fiscal Year Ended
	October 31, 2020		October 31, 2019			October 31, 2018
Balance at beginning of year	$	2.4	$	2.1		$	2.6
Additions (reductions) for tax positions in prior year		0.2		0.3			0.3
Additions for tax positions in current year		0.1		0.1			0.3
Cash settlements with taxing authorities		—		—			(0.2	)
Statute of limitations		—		(0.1	)		(0.9	)
Balance at end of year	$	2.7	$	2.4		$	2.1

If recognized, $3.1 million, $2.6 million, and $2.2 million of the Company’s unrecognized tax benefits as of October 31, 2020, October 31, 2019 and October 31, 2018, respectively, would affect the Company’s effective income tax rate.